CRIS Curis Inc.

1.09
+0.05  (+5%)
Previous Close 1.04
Open 1.04
Price To Book 54.5
Market Cap 36093329
Shares 33,113,146
Volume 114,695
Short Ratio
Av. Daily Volume 385,057

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due mid-2019.
CA-4948
Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 data for Mesothelioma due 2H 2019.
CA170
Solid Tumors and Lymphomas
Approved January 30, 2012.
Vismodegib
Basal Cell Carcinoma
Initial data in DH/DE DLBCL 2H 2019.
Fimepinostat (CUDC-907) and venetoclax
Diffuse-large B-cell lymphoma (DLBCL)

Latest News

  1. Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference
  2. Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
  3. First Mesothelioma Patient Dosed in CA-170 Study
  4. First Eagle Investment Sells Stake in Curis Inc. at Steep Loss
  5. Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
  6. Top 3 Healthcare Penny Stocks for 2018
  7. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  8. Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results
  9. Curis to Present at the 60th Annual Meeting of the American Society of Hematology
  10. Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit
  11. Edited Transcript of CRIS earnings conference call or presentation 1-Nov-18 12:30pm GMT
  12. Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
  13. Curis: 3Q Earnings Snapshot
  14. Curis Reports Third Quarter 2018 Financial Results
  15. Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018
  16. Curis (CRIS) Shares March Higher, Can It Continue?
  17. Who Are The Top Investors In Curis Inc (NASDAQ:CRIS)?